Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-FLT3/CD3 bispecific antibody CLN-049

A T-cell-engaging, humanized, Fc-silenced immunoglobulin G1 (IgG1)-based bispecific antibody directed against both the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2) and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-FLT3/CD3 bispecific antibody CLN-049 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-FLT3/anti-CD3 bispecific antibody CLN-049
FLT3 x CD3 bispecific antibody CLN-049
FLT3 x CD3 bispecific T-cell engager CLN-049
Code name:CLN 049
CLN-049
CLN049
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search